eli lilly retatrutide study Lilly's triple agonist achieves 16.8% weight loss in phase 3 trial Eli Lilly's Phase 3 clinical

GLP-1 medications are not for those with a history of Medullary Thyroid Carcinoma or MEN 2

The cardiovascular markers improved too, with reductions in non-HDL cholesterol and systolic blood pressure that suggest benefits extending well beyond weight management

Even with the profound body weight lowering effects seen in preclinical studies and clinical trials, it is still puzzling to many researchers and clinicians on the mechanism of action of those GLP-1-based therapeutics

BOOST unveiled its new BOOST Advanced Nutritional Shake designed to support nutritional needs during a weight management journey for adults who are on GLP-1s, the company says

Realistic, supportive health coaching available nationwide - focused on sustainable habits, consistency, accountability, and daily guidance throughout your journey

Renal Data System, which integrates data from the Organ Procurement and Transplantation Network that allocates organ transplantation across North America, the U.S